IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer.

Cancer Lett

Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.

Published: July 2013

This study evaluated the potential ability of MK-0646 to inhibit IGF1-mediated biological actions and cell signaling events in Type 1 and Type 2 endometrial cancer. We found that MK-0646 treatment significantly decreased IGF1R expression. In addition, pretreatment with MK-0646 decreased the IGF1-induced phosphorylation of IGF1R, AKT and ERK. Apoptosis analyses showed that MK-0646 abolished the anti-apoptotic effect of IGF1. Furthermore, MK-0646 treatment abolished the IGF1-stimulatory effect on proliferation and enhanced the cytotoxic effect of cisplatin. These findings indicate that specific inhibition of IGF1R could be a useful therapeutic approach for Type 1 and Type 2 endometrial cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2013.02.009DOI Listing

Publication Analysis

Top Keywords

endometrial cancer
12
type type
8
type endometrial
8
mk-0646 treatment
8
mk-0646
5
igf1r-directed targeted
4
targeted therapy
4
therapy enhances
4
enhances cytotoxic
4
cytotoxic chemotherapy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!